Skip to content

An Investigational Scan (MRI With Dixon Based Sequences) in Detecting Prostate Cancer

Evaluation of MRI With Dixon Based Sequences in the Detection of Prostate Cancer

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05047965
Enrollment
65
Registered
2021-09-17
Start date
2013-04-25
Completion date
2027-02-02
Last updated
2026-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Carcinoma

Brief summary

This trial studies the use of magnetic resonance imaging (MRI) with Dixon based imaging sequences in detecting prostate cancer. MRI uses radio waves and a powerful magnet linked to a computer to create detailed pictures of areas inside the body. Researchers hope to learn if using a modified MRI scan technique with Dixon based imaging sequencing will help to produce better images of prostate cancer than the standard of care MRI scan technique.

Detailed description

PRIMARY OBJECTIVES: I. Evaluate prospectively the accuracy of Dixon based sequences in detection of intraprostatic tumor nodules. II. Determine the sensitivity, specificity, positive and negative predictive value of Dixon based sequences in assessment of extraprostatic tumor extension and lymph node involvement. SECONDARY OBJECTIVES: I. Compare the accuracy of Dixon based sequences versus multiparametric diffusion weighted imaging including diffusion tensor imaging in tumor detection and extraprostatic extension. II. Compare the accuracy of Dixon based sequences in detection of transition zone tumors. III. Determine the optimal scanning parameters for Dixon based sequences in the imaging of prostate adenocarcinoma. OUTLINE: Patients undergo MRI with additional Dixon based sequences with fat and water over a total of 49 minutes.

Interventions

PROCEDUREDixon MRI

Undergo Dixon MRI

PROCEDUREMagnetic Resonance Imaging

Undergo standard MRI

Sponsors

M.D. Anderson Cancer Center
Lead SponsorOTHER
National Cancer Institute (NCI)
CollaboratorNIH

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Biopsy proven prostate cancer patients who are scheduled to undergo prostatectomy. * Patient who is scheduled to have a clinically indicated staging endorectal prostate MRI exam. * Patients who have signed their informed consent form to undergo the study.

Exclusion criteria

* Known prior hormone ablation or radiation therapy (pelvic or prostate). * Patients who do not want to undergo prostatectomy and prefer other therapy or surveillance. * Contraindication to conventional MR imaging (e. g. metal implants, pace maker, etc.).

Design outcomes

Primary

MeasureTime frameDescription
Detection of at least one or more prostate lesions with Dixon sequencingthrough study completion, an average of 1 yearWill evaluate and compare the accuracy of Dixon based sequencing to the conventional T2 weighted sequencing for detection of intraprostatic tumor and extraprostatic tumor extension. Lesions will be within any of six regions of the prostate: left apex, left mid, left base, right apex, right mid, and right base. The relative sensitivity and specificity of the two sequencing methods will be compared using an adjusted McNemar's test for clustered data where clusters consist of the matched pairs of within patient-zone observations. The primary analysis will also provide 95% confidence intervals for marginal sensitivity and specificity using a generalized linear mixed model.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORGaneshan Dhakshina Moorthy

M.D. Anderson Cancer Center

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 16, 2026